Table VI.

Results from the cohort study for the risk of recurrent VTE stratified by glucocorticoid use at the time of first venous thromboembolism, excluding patients with malignancy. All 2547 patients with a first VTE from the MEGA Study (the Netherlands, 1999–2004) who were linked to the Stichting Farmaceutische Kengetallen (SFK) data register were included in these analyses.

Oral glucocorticoids	Observation years	Recurrent events	IRR per 1000 person‐years (95% CI)	HR (95% CI)	HR (95% CI)*
Provoked 1st VTE/no glucocorticoids	7907	161	20·36 (17·39; 23·76)	Reference	Reference
Unprovoked 1st VTE/no glucocorticoids	3447	156	45·26 (38·68; 52·94)	2·22 (1·78; 2·77)	1·64 (1·32; 2·13)
Provoked 1st VTE/glucocorticoids	207	10	48·21 (25·89; 89·58)	2·27 (1·24; 4·39)	2·20 (1·21; 4·24)
Unprovoked 1st VTE/glucocorticoids	64	5	78·43 (32·56; 188·32)	3·58 (1·47; 8·84)	2·44 (1·19; 7·34)

1st VTE, first venous thromboembolism; CI, confidence interval; HR, hazard ratio; IRR, incidence rate ratio; MEGA study, Multiple Environmental and Genetic Assessment of Risk Factors for Venous Thrombosis Case‐Control Study.

^*Adjusted for age and sex.